Serum levels of prolidase and ischemia modified albumin in patients with multiple sclerosis

J Clin Exp Invest 2012;3(4):518-520.

https://doi.org/10.5799/ahinjs.01.2012.04.0213

OPEN ACCESS

Download Full Text (PDF)

Abstract

Objectives: Increased levels of free radicals and oxidant molecules and decreased levels of antioxidant molecules have been defined in patients with multiple sclerosis (MS). Ischemia-modified albumin (IMA) levels have been advocated as a biomarker for evaluating the oxidative stress status. The aim of this study was to investigate the relationship between oxidative stress and MS.
Materials and methods: We compared serum ischemia modified albumin levels and prolidase activity of 42 patients with MS (30 female, 12 male) and 30 age-matched healthy controls (21 female, 9 male).
Results: Ischemia modified albumin levels of MS patients (73,07±26,53 ng/mL) were significantly higher than those of controls (60,18±18,01 ng/mL) (p=0.024). However, there were no significant differences in prolidase levels between patients and healthy controls (p=0.856).
Conclusions: Increased ischemia modified albumin levels, supports the role of oxidative stress in patients with multiple sclerosis.

Keywords

Multiple sclerosis, ischemia modified albumin, prolidase, oxidative stress

Citation

Çevik MU, Yücel Y, Arıkanoğlu A, Varol S, Akıl E, Yüksel H, et al. Serum levels of prolidase and ischemia modified albumin in patients with multiple sclerosis. J Clin Exp Invest. 2012;3(4):518-20. https://doi.org/10.5799/ahinjs.01.2012.04.0213